- Home
- SCNX vs NLSP Comparison
SCNX vs NLSP Comparison
Compare SCNX & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- NLSP
- Stock Information
- Founded
- SCNX 2010
- NLSP 2015
- Country
- SCNX United States
- NLSP Switzerland
- Employees
- SCNX N/A
- NLSP N/A
- Industry
- SCNX Other Pharmaceuticals
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- NLSP Health Care
- Exchange
- SCNX Nasdaq
- NLSP Nasdaq
- Market Cap
- SCNX 14.4M
- NLSP 12.4M
- IPO Year
- SCNX 2020
- NLSP 2021
- Fundamental
- Price
- SCNX $0.96
- NLSP $2.68
- Analyst Decision
- SCNX
- NLSP
- Analyst Count
- SCNX 0
- NLSP 0
- Target Price
- SCNX N/A
- NLSP N/A
- AVG Volume (30 Days)
- SCNX 125.4K
- NLSP 325.4K
- Earning Date
- SCNX 08-10-2025
- NLSP 07-07-2025
- Dividend Yield
- SCNX N/A
- NLSP N/A
- EPS Growth
- SCNX N/A
- NLSP N/A
- EPS
- SCNX N/A
- NLSP N/A
- Revenue
- SCNX $146,901.00
- NLSP N/A
- Revenue This Year
- SCNX N/A
- NLSP N/A
- Revenue Next Year
- SCNX N/A
- NLSP N/A
- P/E Ratio
- SCNX N/A
- NLSP N/A
- Revenue Growth
- SCNX N/A
- NLSP N/A
- 52 Week Low
- SCNX $0.69
- NLSP $1.30
- 52 Week High
- SCNX $23.77
- NLSP $16.00
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- NLSP 62.59
- Support Level
- SCNX N/A
- NLSP $2.19
- Resistance Level
- SCNX N/A
- NLSP $2.54
- Average True Range (ATR)
- SCNX 0.00
- NLSP 0.19
- MACD
- SCNX 0.00
- NLSP -0.01
- Stochastic Oscillator
- SCNX 0.00
- NLSP 57.89
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.